|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
ES2137353T3
(es)
*
|
1993-01-08 |
1999-12-16 |
Astra Ab |
Nuevos derivados esteroides especificos del colon o del ileon.
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
JP2007504123A
(ja)
*
|
2003-08-29 |
2007-03-01 |
ランバクシー ラボラトリーズ リミテッド |
Ｉｖ型ホスホジエステラーゼの阻害剤
|
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
CN1942470A
(zh)
|
2004-04-09 |
2007-04-04 |
默克公司 |
Akt活性抑制剂
|
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
|
WO2007031838A1
(en)
|
2005-09-16 |
2007-03-22 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
AU2006305619A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
CA2626628A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
EP2066661A2
(en)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
MX2009003100A
(es)
*
|
2006-09-22 |
2009-05-11 |
Ranbaxy Lab Ltd |
Inhibidores de fosfodiesterasa tipo iv.
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
DK2099442T3
(en)
|
2006-12-26 |
2015-02-16 |
Pharmacyclics Inc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
HRP20120361T1
(hr)
*
|
2007-03-14 |
2012-05-31 |
Ranbaxy Laboratories Limited |
DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
|
|
AU2008269154B2
(en)
|
2007-06-27 |
2014-06-12 |
Merck Sharp & Dohme Llc |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
CN102482318B
(zh)
*
|
2009-09-11 |
2015-11-25 |
奇斯药制品公司 |
异噁唑烷衍生物
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
CN104945382B
(zh)
|
2009-10-14 |
2020-02-07 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
|
WO2011097594A2
(en)
|
2010-02-08 |
2011-08-11 |
Kinagen, Inc. |
Therapeutic methods and compositions involving allosteric kinase inhibition
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2699568A1
(en)
|
2011-04-21 |
2014-02-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
NZ621221A
(en)
|
2011-09-13 |
2016-07-29 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
EP2888255B1
(en)
|
2012-08-24 |
2018-07-18 |
Board of Regents, The University of Texas System |
Heterocyclic modulators of hif activity for treatment of disease
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
KR20150060724A
(ko)
|
2012-09-28 |
2015-06-03 |
머크 샤프 앤드 돔 코포레이션 |
Erk 억제제인 신규 화합물
|
|
RS56680B1
(sr)
|
2012-11-28 |
2018-03-30 |
Merck Sharp & Dohme |
Kompozicije i postupci za lečenje kancera
|
|
MX373639B
(es)
|
2012-12-20 |
2020-05-04 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3475275B1
(en)
|
2016-06-23 |
2024-04-10 |
Merck Sharp & Dohme LLC |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
KR20190074310A
(ko)
|
2016-11-08 |
2019-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
IL270594B2
(en)
|
2017-05-18 |
2024-06-01 |
Regeneron Pharma |
Cyclodextrin protein drug conjugates
|
|
CN111601619A
(zh)
|
2017-11-07 |
2020-08-28 |
里珍纳龙药品有限公司 |
用于抗体药物偶联物的亲水性连接体
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
MA50259A1
(fr)
|
2018-01-08 |
2021-07-29 |
Regeneron Pharma |
Stéroïdes et leurs conjugués-anticorps
|
|
JP7590871B2
(ja)
|
2018-05-09 |
2024-11-27 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
抗ｍｓｒ１抗体及びその使用方法
|
|
KR20210046009A
(ko)
|
2018-08-07 |
2021-04-27 |
머크 샤프 앤드 돔 코포레이션 |
Prmt5 억제제
|
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US12441730B2
(en)
|
2019-12-17 |
2025-10-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP4076459A4
(en)
|
2019-12-17 |
2023-12-20 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EP4077282A4
(en)
|
2019-12-17 |
2023-11-08 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CA3265870A1
(en)
|
2022-09-02 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses
|
|
KR20250079227A
(ko)
|
2022-10-25 |
2025-06-04 |
머크 샤프 앤드 돔 엘엘씨 |
엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
|
|
IL321395A
(en)
|
2022-12-14 |
2025-08-01 |
Merck Sharp & Dohme Llc |
Auristatin cargo-linkers, pharmaceutical compounds, and their uses
|